Cargando…

Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure

BACKGROUND: Mucopolysaccharidosis type I (MPS-I) is a lysosomal storage disorder characterized by progressive multi-organ disease. The standard of care for patients with the severe phenotype (Hurler syndrome, MPS I-H) is early hematopoietic stem cell transplantation (HSCT). However, skeletal disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langereis, Eveline J, Borgo, Andrea, Crushell, Ellen, Harmatz, Paul R, van Hasselt, Peter M, Jones, Simon A, Kelly, Paula M, Lampe, Christina, van der Lee, Johanna H, Odent, Thierry, Sakkers, Ralph, Scarpa, Maurizio, Schafroth, Matthias U, Struijs, Peter A, Valayannopoulos, Vassili, White, Klane K, Wijburg, Frits A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852175/ https://www.ncbi.nlm.nih.gov/pubmed/24088413 http://dx.doi.org/10.1186/1750-1172-8-155

Ejemplares similares

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Treatment of thoracolumbar kyphosis in patients with mucopolysaccharidosis type I: results of an international consensus procedure
por: Kuiper, Gé-Ann, et al.
Publicado: (2019)

Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications
por: Kuiper, Gé-Ann, et al.
Publicado: (2018)

An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life
por: Kingma, Sandra DK, et al.
Publicado: (2013)

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management
por: Solanki, Guirish A., et al.
Publicado: (2013)

Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure
por: de Ru, Minke H, et al.
Publicado: (2011)

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
por: Hendriksz, Christian J., et al.
Publicado: (2014)

Prediction of phenotypic severity in mucopolysaccharidosis type IIIA
por: Knottnerus, Suzan J. G., et al.
Publicado: (2017)

Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome
por: Pal, Abhijit Ricky, et al.
Publicado: (2015)

Easy‐to‐use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment
por: Tylki‐Szymańska, Anna, et al.
Publicado: (2018)

Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Valstar, Marlies J, et al.
Publicado: (2011)

Preconception expanded carrier screening: a focus group study with relatives of mucopolysaccharidosis type III patients and the general population
por: Conijn, Thirsa, et al.
Publicado: (2021)

Attitudes of relatives of mucopolysaccharidosis type III patients toward preconception expanded carrier screening
por: Nijmeijer, Stephanie C. M., et al.
Publicado: (2020)

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
por: Braunlin, Elizabeth A., et al.
Publicado: (2011)

Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder
por: Wijburg, Frits A, et al.
Publicado: (2013)

Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype
por: Valstar, Marlies J., et al.
Publicado: (2010)

Anaesthesia and airway management in mucopolysaccharidosis
por: Walker, Robert, et al.
Publicado: (2012)

Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
por: Bugiani, Marianna, et al.
Publicado: (2023)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Diagnosis and Management of Carpal Tunnel Syndrome in Children with Mucopolysaccharidosis: A 10 Year Experience
por: Dabaj, Ivana, et al.
Publicado: (2019)

Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux–Lamy syndrome): under-recognized and challenging to diagnose
por: Lachman, Ralph S., et al.
Publicado: (2014)

Growth patterns in patients with mucopolysaccharidosis VII
por: Montaño, Adriana M., et al.
Publicado: (2023)

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
por: Harmatz, Paul R., et al.
Publicado: (2013)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses
por: Langereis, Eveline J., et al.
Publicado: (2015)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients
por: Leiro, Beth, et al.
Publicado: (2021)

Pregnancy in patients with mucopolysaccharidosis: a case series
por: Stewart, Fiona J., et al.
Publicado: (2016)

Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I
por: Lund, Troy C., et al.
Publicado: (2020)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
por: Meijer, O. L. M., et al.
Publicado: (2016)

Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey
por: Lau, Heather, et al.
Publicado: (2023)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Transition of patients with mucopolysaccharidosis from paediatric to adult care
por: Lampe, C., et al.
Publicado: (2019)

Implementation by simulation; strategies for ultrasound screening for hip dysplasia in the Netherlands
por: Ramwadhdoebe, Sabrina, et al.
Publicado: (2010)

Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I
por: Dickson, P.I., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k8m69atqe3tvoi11m9n4o67vla